SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001798749-23-000039
Filing Date
2023-05-15
Accepted
2023-05-15 16:11:52
Documents
58
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20230331x10q.htm   iXBRL 10-Q 1707260
2 EX-31.1 tmb-20230331xex31d1.htm EX-31.1 9937
3 EX-31.2 tmb-20230331xex31d2.htm EX-31.2 9958
4 EX-32.1 tmb-20230331xex32d1.htm EX-32.1 5420
5 EX-32.2 tmb-20230331xex32d2.htm EX-32.2 5456
  Complete submission text file 0001798749-23-000039.txt   6749470

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20230331.xsd EX-101.SCH 31152
7 EX-101.CAL tmb-20230331_cal.xml EX-101.CAL 48756
8 EX-101.DEF tmb-20230331_def.xml EX-101.DEF 129270
9 EX-101.LAB tmb-20230331_lab.xml EX-101.LAB 309496
10 EX-101.PRE tmb-20230331_pre.xml EX-101.PRE 256670
52 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230331x10q_htm.xml XML 1390137
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

IRS No.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40544 | Film No.: 23922359
SIC: 2834 Pharmaceutical Preparations